

REQUEST FOR ACCESS TO AN APPLICATION UNDER 37 CFR 1.14(e)

RECEIVED
NOV 01 2002
File Information Unit

In re Application of _____

Application Number

07/ 746 020

Filed

8-15-91

Art. Unit

Examiner

Assistant Commissioner for Patents
Washington, DC 20231

Paper No. 13

1. ☒ I hereby request access under 37 CFR 1.14(e)(2) to the application file record of the above-identified ABANDONED Application, which is not within the file jacket of a pending Continued Prosecution Application (CPA) (37 CFR 1.53(d)) and is: (CHECK ONE)

☒ (A) referred to in:

United States Patent Application Publication No. 5541206, page _____, line _____,

United States Patent Number _____, column _____, line _____, or

an International Application which was filed on or after November 29, 2000 and which

designates the United States, WIPO Pub. No. _____, page _____, line _____.

- ☐ (B) referred to in an application that is open to public inspection as set forth in 37 CFR 1.11(b) or 1.14(e)(2)(i), i.e., Application No. _____, paper No. _____, page _____, line _____.

2. ☐ I hereby request access under 37 CFR 1.14(e)(1) to an application in which the applicant has filed an authorization to lay open the complete application to the public.

Henry Duong
Signature

11-1-02

Date

HENRY DUONG
Typed or printed name

FOR PTO USE ONLY

Approved by: _____

(initials)

Unit: _____



US005541206A

United States Patent [19]**Kempf et al.**[11] **Patent Number:** **5,541,206**[45] **Date of Patent:** **Jul. 30, 1996**[54] **RETROVIRAL PROTEASE INHIBITING COMPOUNDS**[75] Inventors: **Dale J. Kempf**, Libertyville; **Daniel W. Norbeck**, Crystal Lake; **Hing Leung Sham**; **Chen Zhao**, both of Gurnee, all of Ill.[73] Assignee: **Abbott Laboratories**, Abbott Park, Ill.[21] Appl. No.: **423,387**[22] Filed: **Apr. 25, 1995****Related U.S. Application Data**

[63] Continuation of Ser. No. 158,587, Dec. 2, 1993, abandoned, which is a continuation-in-part of Ser. No. 998,114, Dec. 29, 1992, abandoned, which is a continuation-in-part of Ser. No. 777,626, Oct. 23, 1991, abandoned, which is a continuation-in-part of Ser. No. 746,020, Aug. 15, 1991, abandoned, which is a continuation-in-part of Ser. No. 616,170, Nov. 20, 1990, abandoned, which is a continuation-in-part of Ser. No. 518,730, May 9, 1990, Pat. No. 5,142,056, which is a continuation-in-part of Ser. No. 456,124, Dec. 22, 1989, abandoned, which is a continuation-in-part of Ser. No. 405,604, Sep. 8, 1989, abandoned, which is a continuation-in-part of Ser. No. 355,945, May 23, 1989, abandoned.

[51] Int. Cl.⁶ **A61K 31/425**; **C07D 413/12**; **C07D 417/12**[52] U.S. Cl. **514/365**; **548/204**; **548/194**; **548/187**; **548/235**; **548/227**; **548/228**; **548/229**; **514/374**; **514/369**; **514/370**; **514/376**; **514/377**[58] Field of Search **514/365**, **374**, **514/369**, **370**, **376**, **377**; **548/204**, **194**, **187**, **235**, **227**, **228**, **229**[56] **References Cited****U.S. PATENT DOCUMENTS**

5,354,866 10/1994 Kempf et al. 546/265

FOREIGN PATENT DOCUMENTS346847B1 12/1989 European Pat. Off. .
393445B2a 10/1990 European Pat. Off. .
393445B2 10/1990 European Pat. Off. .
402646B6 12/1990 European Pat. Off. .428849B12 5/1991 European Pat. Off. .
428849B12a 5/1991 European Pat. Off. .
441192B3 8/1991 European Pat. Off. .
441192B3a 8/1991 European Pat. Off. .
486948B5 5/1992 European Pat. Off. .
3829594B1a 3/1990 Germany .
3829594B1 3/1990 Germany .
4003575B4 8/1992 Germany .
4003575B4a 8/1992 Germany .
WO88/
02374B7 4/1988 WIPO .
WO92/
00948B9 8/1990 WIPO .
WO90/
09191B8a 8/1990 WIPO .
WO90/
09191B8 8/1990 WIPO .
WO91/
18866B10 12/1991 WIPO .
WO92/
06996B11 4/1992 WIPO .
WO92/
20665B13 11/1992 WIPO .
WO93/
01174B14 1/1993 WIPO .**OTHER PUBLICATIONS**

Wade Jr. Organic Chemistry p. 349 1987 by Prentice—Hall, Inc.

Zeffren et al. The Study of Enzyme Mechanism. p. 87. 1974.


Shutske et al. J. Med. Chem. 1989. 32. 1805–1813.

Primary Examiner—Jane Fan

Attorney, Agent, or Firm—Steven R. Crowley

[57] **ABSTRACT**

A retroviral protease inhibiting compound of the formula:



is disclosed.

19 Claims, No Drawings